Konstantinos N. Aprilakis, MD, joined Stifel Financial as a managing director and senior analyst covering the biotechnology sector. He is based in the firm’s New York office.

“We are thrilled to have Konstantinos on board as we continue to expand our biotech research team,” Keith Gay, director of research for Stifel, said. “Konstantinos has quickly proven himself to be an outstanding biotech analyst and one of the best in the rapidly growing oncology area.”

Aprilakis was most recently a director and senior biotechnology research analyst at Deutsche Bank. Prior to that, he was a vice president and senior biotechnology research analyst at JMP Securities. He also has more than five years of experience in the medical research field, including stints at both Weill Cornell Medical College and Stony Brook University.

“I am extremely excited to be joining Stifel,” Aprilakis said. “I’m particularly impressed by Stifel’s momentum in healthcare and look forward to continuing the expansion of Stifel’s biotech research effort.”

With this hire, Stifel has a global research team of 36 healthcare professionals, including 10 senior analysts, covering 164 companies within the biotechnology, healthcare providers, medical technology and supplies, and specialty pharmaceutical sectors.

In addition to providing research, Stifel also supports clients operating in or investing in the healthcare sector in multiple ways, including:

  • Market making in more than 800 stocks across the healthcare spectrum
  • An investment banking team that has raise more than $68 billion in capital since 2010

Stifel Financial is a financial services holding company headquartered in St. Louis that conducts its banking, securities and financial services business through several wholly-owned subsidiaries.